Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 12, 2024 | June 14, 2024 |
| IPI Legacy Liquidation CoIMPL · Entity 15659 | Director | June 16, 2023 | June 20, 2023 |
| Q32 Bio Inc.FIXX · Entity 5594 | Director | April 02, 2018 | May 16, 2018 |
| SOLENO THERAPEUTICS INCSLNO · Entity 46432 | Director | June 11, 2018 | June 18, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2034-06-11 | Direct | 22,000 |
Reported balance
After 2024-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 22,000 · Balance 22,000 F1: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
IPI Legacy Liquidation Co
Report date June 16, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2033-06-15 | Direct | 13,222 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 13,222 · Balance 13,222 F1: The option is 100% vested on June 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is 100% vested on June 16, 2024.
Q32 Bio Inc.
Report date April 02, 2018 · Filed May 16, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 909,742 |
Reported balance
After 2018-04-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-04-02 · Grant · Acquired 250,000 · Balance 909,742 F1: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
SOLENO THERAPEUTICS INC
Report date June 11, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2028-06-11 | Direct | 15,931 |
Reported balance
After 2018-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-11 · Grant · Acquired 15,931 · Balance 15,931 F1: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verona Pharma plc
Report date October 07, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2025-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-10-07 · Disposition to issuer · Disposed 93,472 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2033-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-07 · Disposition to issuer · Disposed 96,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-07 · Disposition to issuer · Disposed 240,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-10-07 · Disposition to issuer · Disposed 64,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 64,000 | Not disclosed Strike: $0.78 | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 8 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 64,000 shares Expires 2031-08-08 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 240,000 | Not disclosed Strike: $1.93 | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 7 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 96,000 | Not disclosed Strike: $2.67 | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 6 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,000 shares Expires 2033-04-27 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 5 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 200,000 shares Expires 2032-04-27 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionRestricted Share Unit · Derivative | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 4 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 72,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4 · derivative.exercise_price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerOrdinary Shares | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · nonDerivative · entry 3 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · nonDerivative · entry 2 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 16:38 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerOrdinary Shares | 93,472 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · price: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3 · price: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:18 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074384 · tm2522566-3_4seq1.xml · derivative · entry 3 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Ordinary Shares · 24,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F5 · derivative.exercise_price: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:18 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 3,608 | $13.14 | $47,422.47 |
DisclosureSEC source: 0001104659-25-074384 · tm2522566-3_4seq1.xml · nonDerivative · entry 2 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,472 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs"). F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of 93,472 Ordinary Shares represented by 11,684 ADSs. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:18 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074384 · tm2522566-3_4seq1.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 17:16 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantRestricted Share Units · Derivative | 96,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041399 · tm2513544-8_4seq1.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires not disclosed F1 · security: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.exercise_price: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · shares: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F2 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 23:04 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0000950170-24-073918 · ownership.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 16:17 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001104659-24-054950 · tm2412993-7_4seq1.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 18:38 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 13,222 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-23-038601 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,222 Underlying: Common Stock · 13,222 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option is 100% vested on June 16, 2024. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:21 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-037117 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 16:23 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001104659-23-053020 · tm2314094-8_4seq1.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires 2033-04-27 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 17:05 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 12,789 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001209191-22-037957 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,789 Underlying: Common Stock · 12,789 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option is 100% vested on June 16, 2023. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:28 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001209191-22-036090 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 16:42 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001104659-22-053678 · tm2214046-1_4seq1.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2032-04-27 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2022, October 28, 2022, January 28, 2023 and April 28, 2023. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:18 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012456 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-03-23 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 16:45 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-21-102893 · tm2124631-6_4seq1.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Ordinary Shares · 64,000 shares Expires 2031-08-08 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| July 11, 2021 Filed Jul 13, 2021 17:10 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-21-046571 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2031-07-10 F1 · derivative.exercise_date: The option is 100% vested on July 11, 2022. Read SEC document |
| May 04, 2021 Filed May 5, 2021 17:03 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 10,680 | $0.84 | $8,968.00 |
DisclosureSEC source: 0001104659-21-061801 · tm2115267-3_4seq1.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,080 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.8063 to $0.8525. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of 73,080 Ordinary Shares represented by 9,135 ADSs. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | OtherWarrant (Right to Buy) · Derivative | 17,711 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · derivative · entry 7 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 17,711 shares Expires 2028-07-26 F5 · derivative.exercise_date: The shares subject to this warrant were fully vested prior to exercise. F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | ConversionSeries B Preferred Stock · Derivative | 472,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · derivative · entry 6 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 472,296 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date. F3 · derivative.exercise_date: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date. F3 · derivative.expiration_date: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | ConversionSeries A- 1 Preferred Stock · Derivative | 944,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · derivative · entry 5 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 944,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 62 | $20.00 | $1,240.00 |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 4 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 1,448,286 F4 · kind: Upon closing of the Issuer's IPO, Vivo LP exercised a warrant to purchase 17,711 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo LP paid the exercise price on a cashless basis, resulting in the Issuer withholding 62 share subject to the warrant in order to pay the exercise price and issuing to Vivo LP the remaining 17,649 shares of Common Stock. F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | OtherCommon Stock | 17,711 | $0.07 | $1,239.77 |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 3 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 1,448,348 F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | ConversionCommon Stock | 472,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 2 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 1,430,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:33 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | ConversionCommon Stock | 944,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo PANDA Fund, L.P. Disclosed balance after: 958,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 19:10 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 10,800 | $0.99 | $10,733.04 |
DisclosureSEC source: 0001104659-21-011747 · tm215272-4_4seq1.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,760 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.99375 to $0.99625. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of (i) 29,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 3,625 ADSs); and (ii) 54,760 Ordinary Shares represented by 6,845 ADSs. Read SEC document |
| June 11, 2018 Filed Jun 18, 2018 22:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 15,931 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017052 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,931 Underlying: Common Stock · 15,931 shares Expires 2028-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 16:45 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries B Preferred Stock · Derivative | 659,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009459 · doc4.xml · derivative · entry 3 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 659,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 16:45 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantCommon Stock | 500,000 | $16.00 | $8,000,000.00 |
DisclosureSEC source: 0000899243-18-009459 · doc4.xml · nonDerivative · entry 2 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,159,742 F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 16:45 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionCommon Stock | 659,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009459 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 659,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed May 16, 2018 16:05 UTC Amendment | Q32 Bio Inc. FIXX · Entity 5594 | GrantCommon Stock | 250,000 | $16.00 | $4,000,000.00 |
DisclosureSEC source: 0000899243-18-013061 · doc4a.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 909,742 F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 18:30 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock options · Derivative | 31,160 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008909 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,160 Underlying: Common Stock · 31,160 shares Expires 2028-03-27 F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019. Read SEC document |
| February 05, 2018 Filed Feb 8, 2018 01:06 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,466 | $1.73 | $5,983.36 |
DisclosureSEC source: 0000899243-18-003162 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,153 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018 or $1.7263. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:05 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 11,510 | $0.52 | $5,985.20 |
DisclosureSEC source: 0000899243-17-023583 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,808 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or $0.52. Read SEC document |
| July 06, 2017 Filed Jul 18, 2017 01:03 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 9,811 | $0.61 | $5,984.71 |
DisclosureSEC source: 0000899243-17-018377 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,298 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61. Read SEC document |
| May 08, 2017 Filed May 9, 2017 20:33 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 45,139 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000899243-17-012478 · doc4.xml · derivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,139 Underlying: Common Stock · 45,139 shares Expires 2027-05-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is May 8, 2017) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| April 07, 2017 Filed Apr 14, 2017 01:44 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantCommon Stock | 2,533 | $0.63 | $1,595.79 |
DisclosureSEC source: 0000899243-17-010287 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,117 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63. Read SEC document |
| March 07, 2017 Filed Mar 10, 2017 02:52 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantEmployee Stock Option · Derivative | 20,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0000899243-17-007101 · doc4.xml · derivative · entry 2 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-07 F4 · derivative.exercise_date: One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of the Vesting Commencement Date (which is March 7, 2017), and shall continue to vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider (as defined in the Plan) through each such date. Read SEC document |
| March 07, 2017 Filed Mar 10, 2017 02:52 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantCommon Stock | 94,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007101 · doc4.xml · nonDerivative · entry 1 SHAH MAHENDRA · CIK 0001255449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,584 F1 · shares: The reporting person acquired these securities on March 7, 2017, as consideration for the reporting person's interest as a participant in the management carve-out plan of Essentialis, Inc., which was acquired by the Issuer, through a merger of a wholly-owned subsidiary of Issuer with and into Essentialis on March 7, 2017, pursuant to the Agreement and Plan of Merger dated December 22, 2016, by and among the Issuer, Merger Sub (as defined in the Merger Agreement), Essentialis and the Stockholders Representative (as defined therein) (the "Merger Agreement"). F2 · shares: Continued from Footnote 1 Under the terms of the Merger Agreement, a portion of the merger consideration was held back as partial recourse to satisfy indemnification claims made by the Issuer under the Merger Agreement, and such shares will be issued to former shareholders of Essentialis, participants in Essentialis' management carve-out plan and other service providers of Essentialis, upon the one-year anniversary of the closing of the Merger (subject to the limitations set forth in the Merger Agreement). F3 · price: Under the terms of Essentialis' management carve-out plan, the number of shares issuable to carve-out plan participants was determined using the closing price per share of Issuer common stock on March 7, 2017, or $0.68. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.